Listata, 120 mg 80 pcs

Pharmacodynamics.

Orlistat is a potent, specific and reversible inhibitor of gastrointestinal lipases with prolonged action. Its therapeutic action is carried out in the lumen of the stomach and small intestine and consists in formation of covalent bonding with the active serine site of gastric and pancreatic lipases.

Inactivated enzyme in this case loses the ability to break down food fats coming in the form of triglycerides into absorbable free fatty acids and monoglycerides.

Since unrepaired triglycerides are not absorbed, the resulting decrease in caloric intake into the body leads to a decrease in body weight.

Thus the therapeutic effect of the drug is carried out without absorption into the systemic blood flow. Judging by the results of fecal fat content, the action of orlistat begins 24-48 hours after intake. After discontinuation of orlistat the content of fat in feces in 48-72 hours usually returns to the level before the beginning of therapy.

Clinical efficacy. Patients taking orlistat show greater weight loss compared to patients on diet therapy.

The weight loss begins within the first 2 weeks of starting treatment and continues for 6 to 12 months, even in patients with a negative response to diet therapy. Over 2 years there is a statistically significant improvement in the profile of metabolic risk factors associated with obesity.

In addition, there is a significant reduction in body fat compared to placebo administration. Orlistat is effective in preventing weight gain again.

Re-gain of body weight, no more than 25% of that lost, is observed in about half of the patients, and half of these patients have no re-gain of body weight or even further weight loss is noted.

Overweight or obese patients with type 2 diabetes mellitus taking orlistat for 6 months to 1 year have greater weight loss compared with patients receiving diet therapy alone.

Weight loss is mainly due to a decrease in body fat. During orlistat therapy a statistically and clinically significant improvement in glycemic control is observed. In addition, against the background of orlistat therapy there is a decrease in the dose of hypoglycemic agents, insulin concentration, as well as a decrease in insulin resistance.

Orlistat use for 4 years significantly reduces the risk of type 2 diabetes mellitus (by about 37% compared to placebo). The degree of risk reduction is even greater in patients with baseline impaired glucose tolerance (about 45%).

Maintenance of body weight at a new level is observed during the entire period of the drug administration. When orlistat is used for 1 year in adolescents with obesity the decrease of BMI, fat mass as well as waist and hip circumference is observed as compared to the placebo group.

Also, patients treated with orlistat showed a significant decrease in diastolic BP compared to the placebo group.

Indications

Active ingredient

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Similarities